The N-terminal glycine of the VP4 capsid subunit of poliovirus is covalently modified with myristic acid (C14 saturated fatty acid). To investigate the function of VP4 myristoylation in poliovirus replication, amino acid substitutions were placed within the myristoylation consensus sequence at the alanine residue (4003A) adjacent to the N-terminal glycine by using site-directed mutagenesis methods. Mutants which replace the alanine residue with a small hydrophobic residue such as leucine, valine, or glycine displayed normal levels of myristoylation and normal growth kinetics. Replacement with the polar amino acid histidine (4003A.H) also resulted in a level of myristoylation comparable to that of the wild type. However, replacement of the alanine residue with aspartic acid (4003A.D) caused a dramatic reduction (about 40 to 60%) in myristoylation levels of the VP4 precursors (P1 and VPO). In contrast, no differences in modification levels were found in either VPO and VP4 proteins isolated from mature mutant virions, indicating that myristoylation is required for assembly of the infectious virion. The myristoylation levels of the VPO proteins found in capsid assembly intermediates indicate that there is a strong but not absolute preference for myristoyl-modified subunits during pentamer formation. Complete myristoylation was observed in mature virions but not in assembly intermediates, indicating that there is a selection for myristoyl-modified subunits during stable RNA encapsidation to form the mature virus particle. In addition, even though mutant infectious virions are fully modified, the severe reduction in specific infectivity of both 4003A.D and 4003A.H purified viruses indicates that the amino acid residue adjacent to the N-terminal glycine apparently has an additional role early during viral infection and that mutations at this position induce pleiotropic effects.
Poliovirus is a positive-strand RNA virus whose genome is enclosed in an icosahedrally symmetric shell formed by 60 copies of each of the capsid subunits VP1, VP2, VP3, and VP4 (15) . VP4 subunits are modified at the N-terminal glycine residue with myristate (C14 saturated fatty acid) (9) .
Crystallographic analysis of the virion structure revealed the location of this fatty acid and displayed its extensive involvement in subunit-subunit interactions within this multimeric protein complex. This suggested that myristoyl modification may be important during capsid assembly. Viral mutants lacking myristoylation are nonviable and fail to make viral capsids (22, 23, 32) . However, assembly intermediates have been identified in mutant transfected cells (23) . Other in vitro studies have suggested that myristoylation is necessary for correct proteolytic processing of the capsid protein precursors (18, 22) . To date there is no direct evidence identifying the critical roles of this modification during poliovirus infection.
One experimental strategy is to alter the myristoylation signal sequence. In particular, the identity of the amino acid residue adjacent to the N-terminal glycine appears to affect the modification kinetics of the yeast N-myristoyl transferase (NMT) in vitro (35) (36) (37) . The data presented here demonstrate that normal levels of myristoylation are observed in. poliovirus mutants in which the wild-type alanine residue is replaced with leucine, valine, glycine, or histidine. Replacement of the alanine with an aspartic acid results in downmodulation of the myristoylation process in vivo, leading to partial myristoyl modification of the 4003A .D indicates that an aspartic acid replaces the wild-type alanine at amino acid residue 3 of VP4. To be consistent with the nomenclature used for other poliovirus mutants (2) , the full name of 4003A.D is IC-VP4003A.D.
4003 mutant constructions. Sequences encoding the 5' coding region of the poliovirus genome (from nucleotides 1 to 1641, Mahoney strain) were subcloned into M13mp19. Synthetic deoxyoligonucleotides, corresponding to the region of the poliovirus genome between nucleotides 739 and 759, were synthesized with a random mixture of nucleotides at positions 749, 750, and 751 (Massachusetts Institute of Technology biopolymer facility), thus allowing for a variety of amino acid substitutions to occur at amino acid 3 of the VP4 capsid region. The synthetic oligonucleotides were incorporated by the method of Kunkel (20) . Amino acid substitutions were identified by dideoxynucleotide sequence analysis of individually recovered phage genomes (29) . For specific amino acids of interest, full-length poliovirus genomic cDNAs were generated by replacing the 1.2-kb SfiIAatII wild-type fragment in the pPVM1 plasmid with the identical fragment from the mutant subclone. The sequence of the constructed full-length mutant viral cDNA was determined to confirm the identities and locations of the amino acid substitutions (29) . Sequences of viable mutant viruses were determined by direct sequence analysis of the RNA genome using avian myeloblastosis virus reverse transcriptase (Life Sciences Inc.) (24) .
DNA transfection. HeLa cell monolayers (70 to 80% confluent) in 10-cm-diameter plates were transfected with DEAE-dextran and 1 ,ug of pPVM1 (33) . After incubation for 30 min at room temperature, the cells were incubated for 4 h at 37°C in Dulbecco's modified medium containing 10% FCS. The medium was replaced with 20 ml of Dulbecco's modified medium-10% FCS-1% agarose, and monolayers were incubated for 4 days at 37 or 33°C. Plaques were visualized with 1% crystal violet.
Propagation of virus stocks. Well-isolated plaques were picked from the agar overlay and placed in 1 ml of PBS. Each plaque was amplified by infecting confluent HeLa cell monolayers (107 cells) in 10-cm-diameter plates at low multiplicities of infection (MOI of 0.01 to 0.1). Virus-containing medium was collected 2 days later; titers of the supernatants were determined, and the supernatants were stored at -20°C. These low-MOI stocks were used to infect cells at high multiplicities for all biochemical experiments. To isolate purified virus, HeLa cells (4 x 108) were infected in suspension at an MOI of 10 and incubated at 37°C. At 6 h postinfection (p.i.), infected cells were harvested. The cell pellet was subjected to three cycles of freeze-thaw and subsequently lysed in 10 mM Tris-HCl (pH 7.5)-10 mM NaCl-1.5 mM MgCl2-1% Nonidet P-40 (5 x 107 cells per ml). After removal of the nuclei by centrifugation, virus in cell lysate was purified by CsCl density gradients (28) . Purified virus was equilibrated in TNE (50 mM Tris [pH 7.5], 100 mM NaCl, 0.1 mM EDTA) and stored at -20°C.
Single-cycle growth curves. Suspended HeLa cells (2 x 107) were infected with mutant or wild-type virus at high multiplicities (MOI of 10) . After incubation at room temperature for 30 min, the cells were washed twice with PBS, suspended in 5 ml of minimal essential medium-5% FCS, and incubated at 37°C. At various times p.i., 100-,u aliquots were removed. The virus was released from the cells by multiple cycles of freeze-thaw, and the infectious titer in each sample was determined by plaque assays (8 (12) . Lysates were centrifuged at 900 x g for 10 min at 40C to pellet the nuclei, and equal volumes of supernatants were layered onto 6 to 25% and 10 to 30% linear sucrose gradients in TNM. Protomer and pentamer subunits were isolated from 6 to 25% sucrose gradients after centrifugation at 40C in an SW40 rotor at 40,000 rpm for 16.5 h. Empty capsids and mature virus were isolated from 10 to 30% gradients after centrifugation at 4°C in an SW27.1 rotor at 26,000 rpm for 4 h. Gradients were fractionated and counted. Peak fractions at desired sedimentation values were pooled, dialyzed in TNM, and subjected to SDSpolyacrylamide gel electrophoresis as described above.
Quantitation of myristate modification. Radiolabeled protein bands were identified from the fluorograph and excised from the SDS-polyacrylamide gel. The gel slice was incubated overnight with 1 ml of NCS tissue solubilizer (Amersham) at 37°C. Hydrofluor scintillation liquid was added, and 3H and 35S counts were determined. After subtraction of the background, counts were corrected for differential counting efficiency of the two isotopes and spillover between the counting channels.
RESULTS
To identify the biological roles of myristoylation in poliovirus replication, the myristoyl recognition sequence was mutated at alanine VP4 amino acid residue 3 (4003A), the 4003A.D residue adjacent to the N-terminal glycine (Fig. 1 ). Amino acid differences at this position in synthetic hexa-and octapeptide substrates were shown previously to affect the kinetics in vitro of the yeast NMT (35, 37) , whose substrate specificity appears to largely overlap with the murine NMTs (36) . Thus, by analogy, substitutions at 4003A were likely to affect the kinetics in vivo of the human NMT.
All 4003A mutations that were reconstructed into the full-length infectious clone, except for the arginine substitution, generated viable viral mutants upon transfection into HeLa cell monolayers (Fig. 2) . This is in contrast to the nonviability of all 4002G mutants constructed (22, 32) . No temperature or host range differences were observed (data not shown). The wild-type-like plaque phenotypes of 4003A.G, 4003A.L, and 4003A.V indicated that the glycine, leucine, and valine substitutions did not substantially affect overall viral replication. However, substitutions with charged amino acids generated a nonviable mutant (4003A.R) or viable mutants with small-plaque (4003A.H) or microplaque (4003A.D) phenotypes.
The effects of these 4003A substitutions on myristoyl modification were examined for all viable mutant constructs. The poliovirus RNA genome encodes a single large translational product (220 kDa) from which the capsid protein precursor (P1) and nonstructural protein precursors (P2 and P3) are derived by proteolytic cleavages (19) . P1 (97 kDa) is processed by viral protease 3CD to VPO (37 kDa), VP3 (26 kDa), and VP1 (34 kDa) (39) . VPO cleavage to VP4 (7 kDa) and VP2 (31 kDa) is associated with RNA encapsidation and formation of the mature particle (28) . Consistent with myristoylation of other cellular and viral proteins (11, 38) , the N terminus of P1 is modified cotranslationally with myristate (13; unpublished data); all N-terminus-containing products of P1, namely VPO and VP4, are myristoyl modified (9 fied by CsCl density gradients (data not shown). Assuming that all VP4 and VPO proteins in the wild-type virus are myristoyl modified, the identical 3H/35S ratios indicate that all VP4 and VPO proteins in 4003A.D mutant virions are myristoyl modified. In addition, the yield of particles obtained from 4003A.D-infected cells is reduced by approximately 50% compared with yields from wild-type-infected cells (Table 3) . These results are consistent with a selection for myristoyl-modified proteins occurring during capsid assembly and virion morphogenesis.
Virion assembly is initiated by P1 proteins combining to form pentameric intermediates, which subsequently assemble to form the mature virion. Cleavage of P1, generating the capsid proteins of the mature virion, is required for formation of the pentameric intermediate and subsequent assembly of the intact virion. A number of assembly intermediates have been identified in poliovirus-infected cells. These include the uncleaved capsid precursor or protomer (P1), the cleaved protomer or monomer (VPO-VP3-VP1) (5S), the pentamer (14S), the empty particle (80S), and the RNAcontaining mature virus (150S) (28) . To identify when myristoyl modification is critical during capsid formation, these assembly intermediates were isolated from infected cells on sucrose density gradients, and the relative incorporation of [3H]myristate in VPO was determined ( Table 2 ). The myristoyl levels in the pentamer are between those observed for the whole-cell lysate and the mature virion, suggesting that myristoyl-modified protomers are preferentially utilized to form stable pentamers. This is consistent with an apparent decrease in myristoyl-modified VPO capsid proteins in the protomer pool. Thus, although the nonmyristoylated protomers can be incorporated into pentamer intermediates, there is a strong enrichment at the pentamer stage for myristoyl-modified proteins. However, formation of mature virions with only myristoyl-modified protomer subunits indicates that there is an additional selection for myristoylmodified assembly intermediates. The observation that empty capsids are not fully myristoyl modified indicates that pentamers containing unmodified protomers can assemble to form empty capsids. However, myristoylation levels in the empty capsid are reproducibly lower than that measured for pentamer intermediates, indicating that empty capsids containing pentamers with unmodified protomers appear to accumulate. Thus, selection against unmodified assembly intermediates during formation of the mature virus particle appears to occur late in virion assembly; unmodified protomers are excluded during the final stages of virus formation, i.e., RNA encapsidation and cleavage of VPO to VP2 and VP4.
Pulse-chase experiments examined the role of this modification in the kinetics of capsid assembly. Mutant-and wild-typeinfected cells were labeled at 3 h p.i. with [35S]methionine. After 1 h of labeling, cells were incubated in nonradioactive medium, and maturation of the labeled assembly intermediates into mature virus particles was measured at 5 and 6 h p.i. in sucrose gradients (Fig. 4) . Because overall recovery of 35S label from these gradients was identical at each time point for the wild-type and mutant capsid intermediates, it is 4.31 ± 0.08 a Infected-cell extracts from double-labeling experiments were analyzed in sucrose density gradients, and assembly intermediates were separated according to their sedimentation rates (in parentheses).
b Counts per minute (mean ± standard deviation) for each isotope in each protein band after correction for background, differential counting efficiency, and spillover between the counting channels. Means and standard deviations were calculated from counts per minute obtained from several (more than three) determinations of 10 min each. (Fig. 4, panels 1 and 4) . As expected, upon incubation in nonradioactive medium, there was a rapid accumulation of labeled virions as the label shifted from the protomer, pentamer, and empty-capsid peaks to the mature-virion peak and to a rapidly sedimenting fraction (Fig. 4) . This rapidly sedimenting fraction contains maturevirus aggregates (data not shown). In 4003A.D mutantinfected cells, a 5S peak corresponding to the protomer is the predominant peak observed after 1 h of labeling; small peaks are observed in the pentamer and empty-capsid regions of the gradient, and no labeled virus is observed. Upon incubation in nonradioactive medium, there is a decrease in the protomer peak and notable accumulation of labeled empty capsids. Mature 4003A.D virus is formed during this chase period; however, it accumulates at a much slower rate than is observed in wild-type-infected cells (Fig. 4 , panels 5 and 6). Consistently throughout the labeling and chase periods, larger amounts of protomer and empty capsids are present in mutant-infected cells than in wild-type-infected cells. Slower incorporation of protomers in 4003A.D-infected cells into pentamers induces a transient increase of labeled protomers in the monomer region of the sucrose gradients. The monomer peak decreases as mutant protomers are incorporated into pentamer; however, it remains higher than that observed in wild-type-infected cells. Amounts of labeled wildtype empty capsids decrease; in contrast, mutant empty capsids continue to accumulate during this period. No significant differences in pentamer levels were observed in wild-type-or mutant-infected cells. Accumulation of assembly intermediates is observed only in compartments that show increased levels of non-myristoyl-modified VPO. Thus, myristoylation of capsid precursors is required for efficient entry into the capsid assembly pathway, and preferential selection for myristoyl-modified protomers occurs at at least two stages in this pathway: during formation of the stable pentamer and during RNA encapsidation and formation of the mature virion.
The 4003A.D microplaque phenotypes (Fig. 2) could be explained potentially by partial myristoylation and the slow formation of viral particles, which lead to a reduced yield of viral particles per cell. However, because myristoylation levels in 4003A.H mutant-infected cell lysates and mature virus particles are normal (data not shown), similar explanations would not account for the small-plaque phenotype of the 4003A.H mutant. Virus production was evaluated in single-step growth experiments, and the specific infectivities were determined for all 4003A mutants. As expected by their wild-type-like plaque phenotypes, all other mutants (4003A.G, 4003A.L, and 4003A.V) displayed wild-type kinetics (data not shown). The yield of particles per cell and the specific infectivities were also identical to those of wildtype virus (Table 3 ). Appearance of virus in both 4003A.D and 4003A.H mutant-infected cells was also similar to that in wild-type-infected cells; infectious particles were detected at 4 h p.i., and virus production reached a plateau at 6 h p.i. (Fig. 5) . Consistent with the small-plaque phenotype, infectious virus yield per cell was significantly reduced; maximum yield was consistently 10-and 5-fold lower for 4003A.D and 4003A.H, respectively, than for wild type. Kinetics of RNA synthesis and protein synthesis appear normal (data not shown). In 4003A.D, the twofold reduction in particle yield due to reduced myristoylation levels is insufficient to account for the observed reduced yield of infectious virus in this mutant. Specific infectivities for purified 4003A.D and 4003A.H mutant virus particles are approximately sevenand fivefold lower, respectively, than for wild type (Table 3) . Thus, the reduced yield of infectious 4003A.H and 4003A.D viruses can be explained by the reduced infectivity of the 4003A.H particle and by the reduction of both the infectivity and particle yield of the 4003A.D mutant. Because the VP4 and VPO capsid proteins are fully myristoyl modified in both mutant viruses, this reduction in specific infectivities must be due to substitutions of the aspartic acid and histidine residues for the alanine residue. Thus, substitutions in this N-terminal region of VP4 yield pleiotropic phenotypes. In addition to affecting the kinetics of myristoyl modification by the NMT, the identity of this amino acid residue may be important during the early stages of viral infection.
DISCUSSION
Myristoyl modification is thought to be catalyzed by the host NMT. Thus, the modification levels of the VP4003A mutants provide information on the in vivo substrate specificity of the human NMT. The substrate sequence requirements have been extensively defined only for the yeast NMT in vitro by using synthetic hexa-and octapeptides (35) (36) (37) . Similar to the yeast NMT, the human NMT will efficiently modify sequences with small hydrophobic residues adjacent to the N-terminal glycine (position 3). In addition, the nonviable phenotype of a similarly constructed poliovirus mutant with a proline substitution and the wild-type characteristics of revertants with threonine or serine substitutions at this position (22) suggest that the human NMT will similarly modify sequences with small polar residues (but not proline) at this position. Unlike the yeast NMT, the human NMT will modify substrates containing aspartic acid and histidine residues at the penultimate amino acid position. Because myristoylation is a cotranslational event (20 , uCi/ml, 1, 130 Ci/mmol). At 4 h p.i., a large excess of unlabeled methionine (560 ,uM, final concentration) was added, and the infection was allowed to continue for another 2 h. Aliquots (107 cells each) were harvested at 4, 5, and 6 h p.i. Identical volumes of cell extracts were sedimented in 6 to 25% (panels 1 to 3) and 10 to 30% (panels 4 to 6) linear sucrose gradients. Sedimentation profiles of the labeled assembly intermediates at 4 (panels 1 and 4), 5 (panels 2 and 5), and 6 (panels 3 and 6) h p.i. are shown. Sedimentation rates are indicated (panels 1 and 4).
processing of the P1 precursor (18) :ipation is unclear and requires further study. If the proposed that myristoylation directs or signals membrane ibe structure is formed during pentamer assembly localization of proteins. However, several myristoyl-modisted by the structure of the empty capsid [16] and fied proteins appear to have no association or only transient )gical characterization of pentamer and emptyinteractions with membranes; myristoyl modification is obtermediates [27] ), then the observed hydrophobic served on certain membrane proteins containing signal seins in the mature virion between myristate tails and quences, and myristoylated proteins are not segregated to a myristate and adjacent VP3-VP4 residues may be specific cellular membrane. Thus, if myristoylation is a t during pentamer formation, perhaps providing signal for membrane targeting, the nature of this signal is n sites between monomers or stabilizing structural highly complex. In poliovirus, the modification appears to within the pentamer.
facilitate the assembly of multimeric protein subunits; thus it )yl-modified pentamers are required for assembly appears to play a structural role in stabilizing and/or correct iring or after RNA encapsidation that lead to folding of the capsid subunits that is distinct from its irion formation. Although the mechanism for this potential interaction with cellular membranes. Myristoylais unknown, the woven series of myristate intertion may perform a similar structural role in these other [early helps stabilize the pentamer structure within systems. Thus the structure of the myristoylated protein and re virion. Thus an attractive hypothesis is that the its recognition by appropriate receptors in specific memmoiety is required to help maintain the pentamer branes rather than the presence of the myristoyl moiety per vithin the virion particle during the conformational se may be the targeting mechanism. In this regard, it is Is that occur in the final stages of virion maturation interesting that a plasma membrane protein which specifind after RNA encapsidation. Alternatively, the cally recognizes the myristoylated N-terminus sequence of or intracellular locations of the different intermep60vsrc has been identified (25) . Such structural interactions Ly be altered by the myristoyl moiety such that only might represent elements of a more general mechanism for [-modified intermediates are available for RNA targeting proteins to different cellular compartments. packaging and mature-particle formation.
It is unclear whether pentamers found in mutant-infected cells contain a mixture of modified and unmodified protomers or whether the intermediate levels measured reflect two populations of pentamers: one formed with unmodified protomers and the other formed with modified protomers. Structural arguments based on the location of the myristoyl moieties within the mature virion favor the latter interpreta- 
